CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Capricor Therapeutics Inc (CAPR) is a good buy for a beginner investor with a long-term strategy and a $50,000-$100,000 investment range. The stock has strong positive analyst sentiment, significant upside potential based on recent clinical trial success, and a favorable long-term growth outlook. Despite short-term financial challenges, the company's pipeline and potential FDA approval for its therapy by mid-2026 make it a compelling long-term investment.
The technical indicators are mixed but slightly positive. The MACD is above zero and positively contracting, suggesting mild bullish momentum. The RSI is neutral at 45.133, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot point of 23.727, with key resistance at 25.14 and support at 22.313.
Strong Phase III clinical trial results for Deramiocel, meeting primary and secondary endpoints.
Analysts have significantly raised price targets, with a consensus view of substantial upside (targets range from $45 to $60).
Potential FDA approval for Deramiocel by mid-2026, positioning it as a first-in-class therapy for Duchenne muscular dystrophy.
Favorable long-term sales projections, with risk-adjusted net sales of $1.1B by 2030.
Short-term financial challenges, including a 100% YoY revenue drop and negative gross margin.
High implied volatility (99.
and low IV rank (8.78), indicating limited options trading opportunities for new entries.
No significant hedge fund or insider trading activity to support immediate bullish sentiment.
In Q3 2025, the company reported a 100% YoY revenue drop, with revenue at $0. However, net income improved by 95.68% YoY to -$24,570,647, and EPS increased by 42.11% YoY to -0.54. Gross margin also dropped to 0, reflecting ongoing financial challenges.
Analysts are overwhelmingly positive on CAPR, with multiple firms raising price targets significantly (e.g., B. Riley to $50, Piper Sandler to $45, Oppenheimer to $54, Maxim to $50, H.C. Wainwright to $60, Alliance Global to $48). The consensus is that Deramiocel's clinical profile is strong, with a high probability of FDA approval and significant long-term sales potential.
